BioCentury This Week

Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

The first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showc

Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

Note: This episode was briefly published with an incorrect audio file, which has since been corrected. FDA is prepared to approve psychedelic therapies for chronic psych

Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs

A pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis, most of which stemmed from the Phase III miss of antisense oligon

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCentury This Week podcast

Ep. 384 - Back to School Special: The global FIH trials race

China has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and policymakers around t

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury This Week podcast, B

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA

A baker’s dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On the latest BioCentury This Week podcast, BioCentury’s analysts d

Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs

Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human trials faster and more

Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s

Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product upon which it can ru

Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data

The departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what Vallanc

Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson

After nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding beyond the sector’s tra

Ep. 376 - M&A momentum: 3Q public markets preview

M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCentury’s 3Q26 Public M

Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury Th

Ep. 374 - Parkinson's deep dive & FDA trial reforms

New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioC

Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury Thi

Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market

Ep. 371 - Moving faster at the academia-industry interface

Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too. From AI to NAMs to starting a Phas

Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Wee